Video

Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Related Videos
Related Content
3D illustration of T-cells | Image Credit: © Emile - stock.adobe.com
March 26th 2025

AIM Test Could Help Predict COVID-19 Vaccine Response in Patients With CLL

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Multiple myeloma cells | Image Credit: © LELISAT - stock.adobe.com
March 26th 2025

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Pharmacist holding package of ibrutinib |Image Credit: © CLShebley - stock.adobe.com
March 18th 2025

Real-World Study Supports Ibrutinib Dose Reduction for Managing Adverse Events in CLL

Alexandra Gerlach, Associate Editor
Blood cancer cells | Image Credit: © stock_acc - stock.adobe.com
March 17th 2025

Elotuzumab-Based Regimen Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor